

23rd April 2024

Dear Healthcare Professional

Shortage of ORDINE morphine hydrochloride trihydrate 1 mg/mL oral solution bottle (AUST R 150219) and alternative supply arrangement under Section 19A of the *Therapeutic Goods Act 1989*.

The Australian registered medicine, **ORDINE morphine hydrochloride trihydrate 1 mg/mL oral solution bottle**, sponsored by Arrotex Pharmaceuticals Pty Ltd is unavailable due to commercial changes.

Bridgewest Perth Pharma Pty Ltd (trading as LumaCina) has arranged for the supply of **RA-MORPH morphine hydrochloride trihydrate 1 mg/mL oral solution (NZ)**. This product is NOT registered in Australia and supply is authorised under an approval granted by the Therapeutic Goods Administration (TGA) under Section 19A of the *Therapeutic Goods Act 1989* until 31 October 2024 for the following indications:

*Indicated in adults and children **aged 1 year and above** for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.*

RA-MORPH morphine hydrochloride trihydrate 1mg/mL oral solution (NZ) is registered and marketed in New Zealand therefore all labelling is in English. The formulation and presentation are identical to the Australian registered **ORDINE morphine hydrochloride trihydrate 1 mg/mL oral solution bottle**.

Healthcare professionals should refer to the Australian Product Information for **ORDINE morphine hydrochloride trihydrate 1 mg/mL oral solution bottle** when prescribing **RA-MORPH morphine hydrochloride trihydrate 1 mg/mL oral solution (NZ)** for the above indications. Patients and carers should refer to the Australian Consumer Medicines Information for **ORDINE morphine hydrochloride trihydrate 1 mg/mL oral solution bottle** for further information. These documents are available at: <https://www.ebs.tga.gov.au>.

Adverse Event Reporting

Reporting any suspected adverse event is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **RA-MORPH morphine hydrochloride trihydrate 1 mg/mL oral solution (NZ)** should be reported by healthcare professionals and patients to Bridgewest Perth Pharma Pty Ltd (Medical Information) on 1800 161 156 or by email safety@lumacina.com. Alternatively, this information can be reported to the TGA at <https://www.tga.gov.au/reporting-problems>

Please forward this information to relevant staff members in your organisation.



Bridgewest Perth Pharma Pty Ltd ABN 21 663 385 411
(trading as LumaCina®)
15 Brodie Hall Drive, Technology Park, Bentley, WA
6102, Australia
PO Box 1007, Bentley DC, WA 6983, Australia
Tel 61 8 9362 0666
LumaCina.com.au

For further information, please contact Bridgewest Perth Pharma Pty Ltd (Medical Information) on 1800 161 156 or by email safety@lumacina.com.

Product Procurement

Contact Juno Pharmaceuticals Pty Ltd for supply of Product (Phone +61 3 8888 1288, Email: info@junopharm.com.au)

Yours faithfully

A handwritten signature in blue ink, appearing to read "Mark Weir-Smith".

Mark Weir-Smith
Senior Vice-President Quality and Regulatory Compliance
Bridgewest Perth Pharma Pty Ltd (trading as LumaCina®)

A handwritten signature in black ink, appearing to read "Anthony Boteju".

Anthony Boteju
Vice-President - Sales & Marketing
LumaCina®